全文获取类型
收费全文 | 22310篇 |
免费 | 1744篇 |
国内免费 | 45篇 |
专业分类
耳鼻咽喉 | 209篇 |
儿科学 | 562篇 |
妇产科学 | 411篇 |
基础医学 | 3004篇 |
口腔科学 | 725篇 |
临床医学 | 2255篇 |
内科学 | 4964篇 |
皮肤病学 | 253篇 |
神经病学 | 2115篇 |
特种医学 | 859篇 |
外国民族医学 | 1篇 |
外科学 | 2729篇 |
综合类 | 444篇 |
一般理论 | 29篇 |
预防医学 | 1945篇 |
眼科学 | 585篇 |
药学 | 1648篇 |
中国医学 | 11篇 |
肿瘤学 | 1350篇 |
出版年
2022年 | 123篇 |
2021年 | 300篇 |
2020年 | 189篇 |
2019年 | 291篇 |
2018年 | 343篇 |
2017年 | 286篇 |
2016年 | 311篇 |
2015年 | 359篇 |
2014年 | 531篇 |
2013年 | 888篇 |
2012年 | 1177篇 |
2011年 | 1261篇 |
2010年 | 664篇 |
2009年 | 686篇 |
2008年 | 1236篇 |
2007年 | 1376篇 |
2006年 | 1377篇 |
2005年 | 1377篇 |
2004年 | 1296篇 |
2003年 | 1226篇 |
2002年 | 1231篇 |
2001年 | 418篇 |
2000年 | 359篇 |
1999年 | 379篇 |
1998年 | 319篇 |
1997年 | 280篇 |
1996年 | 259篇 |
1995年 | 264篇 |
1994年 | 204篇 |
1993年 | 198篇 |
1992年 | 308篇 |
1991年 | 252篇 |
1990年 | 281篇 |
1989年 | 245篇 |
1988年 | 269篇 |
1987年 | 260篇 |
1986年 | 221篇 |
1985年 | 239篇 |
1984年 | 226篇 |
1983年 | 206篇 |
1982年 | 232篇 |
1981年 | 250篇 |
1980年 | 199篇 |
1979年 | 194篇 |
1978年 | 161篇 |
1977年 | 130篇 |
1976年 | 100篇 |
1974年 | 124篇 |
1973年 | 100篇 |
1972年 | 98篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
41.
42.
J. O’Byrne S. Eustace M. M. Stephens M. N. M. R. Farahat G. Yanni R. Posten G. S. Panayi S. Sant R. Costello M. Barry J. Hassan C. Feighery B. Bresnihan A. Whelan F. Coakley A. M. de Paor R. B. Reilly E. B. Casey V. J. Tormey G. Kearns K. Gaffney P. J. Freyne M. Callaghan O. FitzGerald D. Veale E. O’Nuallain D. Reen D. Veale M. Farrell O. FitzGerald S. Rogers L. Barnes R. J. Coughlan C. McCarthy M. McDermott D. Hourihane C. O'Morain S. O'Reilly P. Hartley E. Casey L. Clancy F. Mulcahy N. Hall A. Murphy C. Breen D. Kelleher M. Abuzakouk C. O'Farrelly 《Irish journal of medical science》1992,161(6):438-442
43.
Thuy T. Chau Thomas Walter Alan Katz Barry M. Weichman 《Drug development research》1993,28(4):488-495
Pemedolac Na, 1-ethyl-1,3,4,9-tetrahydro-4-(phenylmethyl)-pyrano [3,4-b] indole-1-acetic acid sodium salt, exhibited equipotent analgesic effects after oral, iv, and im administration, suggesting that it is well absorbed. In mouse writhing models, the ED50 values ranged from 0.3 mg (0.81 μmol)/kg (vs. acetylcholine) to 4.3 mg (11.6 μmol)/kg (vs. paraphenylbenzoquinone [PBQ]). In the rat Randall-Selitto model, the ED50 o the compound was approximately 0.001 mg (2.7 nmol)/kg, with a flat dose response curve. The peak effects lasted for 7–9 h, 10–18 h, and 5 h following oral, im, and iv injections, respectively. Intracerebroventricular (i.c.v.) injections of pemedolac Na inhibited the PBQ-induced writing in mice with an ED50 of 43.5 μg (0.12 μmol)/mouse, and this effect was not antagonized by naloxone. It was inactive in the hot plate and tail flick tests, demonstrating that pemedolac Na does not act via an opiate mechanism. These results indicate that pemedolac Na is a viable parenteral and oral analgesic, typified by high analgesic potency, a rapid onset and long duration of action, and an extremely wide safety index. © Wiley-Liss, Inc. 相似文献
44.
David Langton Diana Way Lisbeth Trigg Duncan Blake Barry McGrath 《Clinical and experimental pharmacology & physiology》1990,17(3):219-223
1. The effects of graded treadmill exercise on renal blood flow (RBF) were examined in seven rabbits, in which congestive heart failure (CHF) was produced by the administration of doxorubicin, 1 mg/kg, twice weekly for 8 weeks, and in seven controls. A third group of five rabbits underwent doxorubicin treatment with the addition of surgical section of the left renal sympathetic nerve. 2. During submaximal exercise, there was a small reduction in RBF in controls, which was greatly exaggerated in CHF. 3. In both control and heart failure rabbits, there was a precipitous fall in RBF as exercise fatigue developed. 4. Renal sympathectomy ablated these changes in RBF during exercise. 5. It is concluded that in heart failure there is an exaggerated, sympathetically mediated, diversion of blood flow away from the kidney. The onset of exercise fatigue in both normal and heart failure rabbits is accompanied by a marked intensification of this process. 相似文献
45.
46.
47.
48.
49.
S M Kieran R A Cahill I Browne S J Sheehan D Mehigan M C Barry 《European journal of vascular and endovascular surgery》2006,32(3):305-308
INTRODUCTION: Concern about the potential detrimental side-effects of beta-blockade on pulmonary function often dissuades against their perioperative use in patients undergoing major arterial surgery (especially in those with chronic obstructive pulmonary disease (COPD)). In this study we aimed to establish prospectively the clinical relevance of these concerns. METHODS: After ethics committee approval and individual informed consent, the pulmonary function of twenty patients (mean age 68.7 years (range 43-82), 11 males) scheduled to undergo non-emergency major vascular surgery was studied by recording symptoms and spirometry before and after institution of effective beta-blockade. Fifteen patients (75%) had significant smoking histories (mean pack years/patient=50), while 12 (60%) had COPD. RESULTS: All patients tolerated effective beta-blockade satisfactorily without developing either subjective deterioration in symptoms or significant change on spirometry. The mean change in FEV1 following adequate beta-blockade was 0.05+/-0.24 liters (95% CI -0.06 to +1.61), p=0.35, giving a mean percentage change of 3.18%+/-11.66 (95% CI -2.26 to 8.62). CONCLUSIONS: Previously held concerns about worsening pulmonary function through the short-term use of beta-blockers should not dissuade their perioperative usage in patients with peripheral vascular disease. Furthermore, the accuracy of pulmonary function tests in preoperative assessment and risk stratification also appears unaffected by this therapy. 相似文献
50.